Key Points
- Insider sale: Director Well Daan Van sold 2,861 shares on April 8 at $4.85 totaling $13,875.85 under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding from vested awards, leaving him with 350,808 shares (a 0.81% ownership decrease).
- Fundamentals and analyst outlook: SOPHiA GENETICS reported an EPS miss (‑$0.28 vs. ‑$0.20 expected) with negative margins and ROE, a market cap of about $322M, and mixed analyst coverage—Guggenheim and BTIG have Buy ratings and $7 targets while Weiss Rates Sell, producing an average price target of $7 and a consensus of "Hold."
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) President Ross Muken sold 2,786 shares of the company's stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $4.84, for a total transaction of $13,484.24. Following the transaction, the president owned 695,311 shares in the company, valued at approximately $3,365,305.24. This trade represents a 0.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Ross Muken also recently made the following trade(s):
- On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
- On Tuesday, April 7th, Ross Muken sold 2,424 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total transaction of $11,804.88.
- On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $5,666.57.
SOPHiA GENETICS Stock Performance
SOPH opened at $4.70 on Friday. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.70. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The company has a market cap of $321.90 million, a P/E ratio of -9.22 and a beta of 1.04. The firm's 50-day moving average price is $4.75 and its 200-day moving average price is $4.69.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The company had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. As a group, equities analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the stock. BTIG Research restated a "buy" rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Guggenheim upped their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a report on Monday, January 26th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $7.00.
Check Out Our Latest Research Report on SOPHiA GENETICS
Hedge Funds Weigh In On SOPHiA GENETICS
Several hedge funds and other institutional investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after buying an additional 5,432,871 shares during the period. Akre Capital Management LLC increased its holdings in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after buying an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $6,708,000. Royce & Associates LP acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $2,009,000. Finally, 1492 Capital Management LLC acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $973,000. Institutional investors and hedge funds own 31.59% of the company's stock.
SOPHiA GENETICS News Roundup
Here are the key news stories impacting SOPHiA GENETICS this week:
- Positive Sentiment: Large institutional accumulation — UBS, Akre and several other funds materially increased positions in recent quarters, signaling conviction from some large investors which could provide demand support for the stock.
- Positive Sentiment: Analyst upside — Guggenheim and BTIG have issued Buy ratings and target prices around $7, above the current trading level, giving the stock upside on positive research momentum.
- Neutral Sentiment: Multiple executives sold small blocks of shares under pre‑arranged Rule 10b5‑1 plans to cover tax withholding associated with vested awards; these are routine and reduce the informational signal from insider sales. Representative SEC filing for CEO sales. CEO Form 4
- Neutral Sentiment: Additional planned sales by other insiders (CFO, President, CTO and others) were disclosed; most trades are modest relative to executive holdings and were executed under 10b5‑1 plans — still worth monitoring for short‑term supply impact. Example coverage of a recent insider sale. InsiderTrades article
- Negative Sentiment: Short interest increased ~20% in late March to ~255k shares (≈0.4% of float), raising potential downward pressure and the possibility of elevated volatility if shorts add to positions or cover into thin trading days.
- Negative Sentiment: Recent fundamentals remain challenged — SOPH reported an EPS miss in early March and continues to show negative margins and ROE; analysts still model negative EPS for the year, which keeps valuation sensitivity high.
About SOPHiA GENETICS
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
